Glenmark Pharmaceuticals (NSE:GLENMARK) Cyclically Adjusted Revenue per Share: ₹504.27 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:GLENMARK Glenmark Pharmaceuticals Ltd NSE:GLENMARK
85 GF Score
Price ₹2,318.40
GF Value ₹2,177.91
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Glenmark Pharmaceuticals Cyclically Adjusted Revenue per Share?

Glenmark Pharmaceuticals NSE:GLENMARK -0.07% 85 Cyclically Adjusted Revenue per Share is ₹504.27 as of Jun. 2026. GuruFocus rates NSE:GLENMARK with a GF Score™ of 85/100 and a GF Value™ of ₹2,177.91 (Fairly Valued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Glenmark Pharmaceuticals's adjusted revenue per share for the three months ended in Jun. 2026 was ₹139.301. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹504.27 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Glenmark Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 7.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 6.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Glenmark Pharmaceuticals was 7.80% per year. The lowest was 5.70% per year. And the median was 6.65% per year.

As of today (2026-08-16), Glenmark Pharmaceuticals's current stock price is ₹2318.40. Glenmark Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹504.27. Glenmark Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 4.60.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Glenmark Pharmaceuticals was 4.86. The lowest was 0.59. And the median was 1.56.


Glenmark Pharmaceuticals  (NSE:GLENMARK) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Glenmark Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2318.40/504.27
=4.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Glenmark Pharmaceuticals was 4.86. The lowest was 0.59. And the median was 1.56.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Glenmark Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Glenmark Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Glenmark Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glenmark Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Glenmark Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 387.13 419.09 442.08 461.52 495.07

Glenmark Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 469.28 486.20 491.46 495.07 504.27

NSE:GLENMARK vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Glenmark Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glenmark Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Glenmark Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Glenmark Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


NSE:GLENMARK
85GF Score
Glenmark Pharmaceuticals Ltd NSE:GLENMARK
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Glenmark Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Glenmark Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=139.301/167.3573*167.3573
=139.301

Current CPI (Jun. 2026) = 167.3573.

Glenmark Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 76.982 105.961 121.587
201612 87.259 105.196 138.821
201703 86.013 105.196 136.839
201706 82.519 107.109 128.936
201709 78.790 109.021 120.949
201712 76.908 109.404 117.648
201803 79.624 109.786 121.378
201806 75.491 111.317 113.496
201809 89.999 115.142 130.812
201812 88.879 115.142 129.185
201903 89.534 118.202 126.767
201906 80.870 120.880 111.964
201909 97.986 123.175 133.133
201912 93.467 126.235 123.915
202003 96.125 124.705 129.002
202006 81.811 127.000 107.808
202009 103.011 130.118 132.492
202012 97.853 130.889 125.117
202103 100.236 131.771 127.306
202106 104.367 134.084 130.266
202109 110.747 135.847 136.435
202112 111.274 138.161 134.789
202203 104.945 138.822 126.517
202206 96.354 142.347 113.283
202209 105.704 144.661 122.288
202212 108.542 145.763 124.622
202303 104.884 146.865 119.519
202306 106.195 150.280 118.263
202309 111.855 151.492 123.569
202312 87.174 152.924 95.401
202403 106.972 153.035 116.984
202406 114.243 155.789 122.726
202409 120.482 157.882 127.713
202412 117.002 158.323 123.679
202503 110.800 157.552 117.696
202506 108.351 159.755 113.507
202509 212.667 162.289 219.308
202512 137.696 163.281 141.134
202603 133.238 164.272 135.740
202606 139.301 167.357 139.301

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹504.27 mean?
Glenmark Pharmaceuticals (NSE:GLENMARK) has a Cyclically Adjusted Revenue per Share of ₹504.27 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Glenmark Pharmaceuticals and its competitors.
Is Glenmark Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Glenmark Pharmaceuticals' current Cyclically Adjusted Revenue per Share is ₹504.27. Overall, Glenmark Pharmaceuticals has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Glenmark Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to ZTS?
Glenmark Pharmaceuticals' Cyclically Adjusted Revenue per Share of ₹504.27 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Glenmark Pharmaceuticals and its competitors. Glenmark Pharmaceuticals's current Cyclically Adjusted Revenue per Share is ₹504.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glenmark Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Glenmark Pharmaceuticals (NSE:GLENMARK) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,177.91, compared to a current price of ₹2,318.40 — trading 6.5% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹504.27. Glenmark Pharmaceuticals' overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Glenmark Pharmaceuticals (NSE:GLENMARK), the current Cyclically Adjusted Revenue per Share is ₹504.27 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Glenmark Pharmaceuticals (NSE:GLENMARK) Overvalued in 2026?

Based on GuruFocus' analysis, Glenmark Pharmaceuticals stock appears to be overvalued. The current stock price of ₹2,318.40 is trading 6.5% above its estimated GF Value™ of ₹2,177.91. GuruFocus considers Glenmark Pharmaceuticals to be Fairly Valued.

Key valuation signals for NSE:GLENMARK:

  • Cyclically Adjusted Revenue per Share: ₹504.27
  • GF Value™: ₹2,177.91 vs. price of ₹2,318.40 (6.5% above fair value)
  • GF Score™: 85/100 with 2 warning signs

No single metric tells the full story. See the NSE:GLENMARK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Glenmark Pharmaceuticals Business Description

Other Exchanges 532296:India
Address B. D. Sawant Marg, Glenmark House, Chakala, Off Western Express Highway, Andheri (East), Mumbai, MH, IND, 400099
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities. It has a business presence in different therapeutic areas such as dermatology, respiratory, oncology, diabetes, cardiovascular, and oral contraceptives among others. Geographically, it derives key revenue from India and the rest from North America, Latin America, Europe and the Rest of the world.
85GF Score

Get the complete analysis for NSE:GLENMARK

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,318.40
Price
₹2,177.91
GF Value